Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growth

Shares of Wockhardt surged 8.57% to Rs 1,550 on Tuesday in trading, following a sharp turnaround in its March quarter performance and improved full-year earnings.
The pharmaceutical company reported a net profit of Rs 164 crore in Q4FY26, compared with a loss of Rs 45 crore in the same period last year. Revenue rose 30% year-on-year to Rs 965 crore, up from Rs 743 crore in Q4FY25.

EBITDA also recorded strong growth of 147%, rising to Rs 196 crore from Rs 79 crore a year earlier.


For FY26, Wockhardt posted revenue of Rs 3,373 crore, up 11% from Rs 3,033 crore in the previous year. EBITDA increased 51% to Rs 630 crore from Rs 418 crore, reflecting improved operating performance across segments.

Biotech operations were a key growth driver, contributing Rs 252 crore in the quarter, a 126% increase over Q4FY25. On a full-year basis, biotech revenue rose 27% to Rs 697 crore, supported by strong momentum in emerging markets, where growth exceeded 34%. Expansion was aided by new partnerships and deals across Thailand, Egypt, Algeria, and Latin America, while domestic biotech operations continued to grow at a double-digit pace.

The company reported continued expansion in its product pipeline, with 15 filings, 13 approvals, and 23 launches in international markets. In biosimilars, it recorded 11 filings and 16 approvals, while the NCE segment saw 4 filings and 1 approval. It also secured approvals for EMROK O and EMROK injection in Uganda.

On the valuation front, Wockhardt’s market capitalisation stands at Rs 23,155 crore. The stock has gained 13% over the past month and is currently trading between its 52-week high of Rs 1,868.80 and low of Rs 1,086.70. It trades at a price-to-earnings ratio of 1030.79 and a price-to-sales ratio of 7.66.

From a technical perspective, the 14-day RSI stands at 60.3, indicating neutral momentum, while the stock is trading above all eight key simple moving averages, signalling a broadly bullish trend.

"Wockhardt is showing a strong recovery after a prolonged consolidation, with price reclaiming key short-term moving averages and now approaching a crucial resistance zone around 1550-1600, which also aligns with a prior supply area. The recent breakout attempt is supported by rising volumes and an RSI trending near 70, indicating strong momentum but also nearing overbought territory, so some near-term pause or minor pullback cannot be ruled out. Structurally, the stock has formed a higher low near 1200, signaling a trend reversal bias. A sustained move above 1600 can trigger fresh upside towards 1700–1750 levels, while immediate support lies at 1420 followed by 1350. Traders can maintain a positive bias as long as price holds above 1400, with dips likely to be bought into," says Kunal Kamble, Sr. Technical Research Analyst at Bonanza.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)